Article

SurModics, Merck to collaborate

Eden Prairie, MN-SurModics Inc. and Merck & Co. Inc. have formed a license and research collaboration to pursue the joint development and commercialization of SurModics’ intravitreal implant offering sustained-release delivery of triamcinolone acetonide (I-vation TA) and other products that combine Merck proprietary drug compounds with the drug-delivery system to treat retinal diseases.

Eden Prairie, MN-SurModics Inc. and Merck & Co. Inc. have formed a license and research collaboration to pursue the joint development and commercialization of SurModics’ intravitreal implant offering sustained-release delivery of triamcinolone acetonide (I-vation TA) and other products that combine Merck proprietary drug compounds with the drug-delivery system to treat retinal diseases.

Under the terms of the agreement, Merck will lead and fund the development and commercialization activities and will pay SurModics an up-front licensing fee of $20 million. SurModics may receive up to $288 million more in fees if development is successful and if U.S. and European Union regulatory approvals occur. In addition, Merck will reimburse SurModics for its development activities and will pay royalties to SurModics based on product sales. SurModics will be responsible for manufacturing and supplying clinical and commercial products.

“[This] announcement is an important milestone in the history of SurModics and marks the first license of our sustained drug-delivery platforms in the ophthalmology market,” said Bruce Barclay, president and chief executive officer of SurModics.

The implant is being studied in a phase I human clinical trial, the Sustained Triamcinolone Release for Inhibition of Diabetic Macular Edema study, under an investigational new drug application with the FDA. Nine-month data were presented in May at the Association for Research in Vision and Ophthalmology annual meeting.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.